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A major safety concern with the use of herbal medicinal products (HMP) is their interactions with conventional medicines,
which are often mediated via the cytochrome P450 (CYP) system. Echinacea is a widely used over-the-counter HMP, with proven
immunomodulatory properties. Its increasing use makes research into its safety an urgent concern. Previously, we showed that
Echinacea extracts and its alkylamides (thought to be important for Echinacea’s immunomodulatory activity) mildly inhibit
the enzymatic activity of the main drug metabolising CYP isoforms, but to this date, there is insufficient work on its ability to
alter CYP expression levels. We now report for the first time the effect of a commercial Echinacea extract (Echinaforce) and four
Echinacea alkylamides on the transcription of the major drug metabolizing enzyme CYP3A4. HepG2 cells were exposed for 96
h to clinically relevant concentrations of Echinaforce (22, 11.6 and 1.16 μg mL−1) or the alkylamides (1.62 and 44 nM). CYP3A4
mRNA levels were quantified using real-time reverse transcription polymerase chain reaction (RT-PCR). Neither Echinaforce nor
the alkylamides produced any significant changes in the steady-state CYP3A4 mRNA levels, under these conditions. In contrast,
treatment with 50 μM rifampicin resulted in a 3.8-fold up-regulation over the vehicle control. We conclude that Echinaforce is
unlikely to affect CYP3A4 transcriptional levels, even at concentrations which can inhibit the enzymatic activity of CYP3A4.
Overall, our data provides further evidence for the lack of interactions between Echinacea and conventional drugs.
1. Introduction
Interactions between herbal medicinal products (HMP) and
conventional drugs are a major safety concern. One of the
main pathways for such interactions is via the cytochrome
P450 (CYP) enzymes. Direct inhibition or induction of CYP
isoforms by HMP can alter the metabolism of conventional
drugs, leading to adverse effects. An example showcasing the
significance of such interactions is St. John’s Wort, which
has been shown to affect the pharmacokinetics of several
important drugs [1], highlighting the need for in vitro
investigations into the possible interactions of HMP with
CYP isoforms [2].
Echinacea is a popular HMP, well known for its immuno-
modulatory properties and used worldwide for the treatment
of upper respiratory tract infections [3–5]. Previously, we
investigated in detail the ability of Echinacea to inhibit
various CYP isoforms [6]. We showed that Echinacea and
some of its alkylamides weakly inhibit a number of major
CYP isoforms. We also screened 10 commercially available
Echinacea liquid preparations (ELP) for CYP3A4 inhibitory
activity and found that it varied considerably (IC50 values
12.7–1817 μg mL−1) [6].
Aside from direct enzymatic inhibition, HMPs can
affect CYP activity by altering their transcriptional activity
(i.e., induce or suppress CYP expression). Altering CYP
expression will affect drug metabolism in three different
ways. It can alter drug elimination, pro-drug activation, or
drug bioactivation (i.e., conversion to toxic metabolites), all
of which can have serious consequences [7, 8].
CYP gene induction may occur via the action of three
intracellular receptors: the aryl hydrocarbon receptor (AhR),
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the constitutive androstane receptor (CAR) and the pregnane
X receptor (PXR) [7, 8]. PXR is believed to be the main
mediator of CYP3A gene induction [7]. The mechanism of
CYP induction is shown in Figure 1. An important example
of CYP induction by HMP is St John’s Wort (Hypericum
perforatum), which has been shown to induce CYP3A4
through PXR activation and can significantly decrease the
plasma concentration of concurrently used medicines (e.g.,
ciclosporin indinavir and the oral contraceptive) [9]. Other
natural products, which can induce CYP expression, include
kava kava (Piper methysticum G. Forster), used to treat
anxiety and Qing hao (Artemisia ammua) used traditionally
as an antipyretic [9].
To date, there is limited data on the induction of CYP
enzymes by ELP. Hellum and colleagues [10] found that a
commercial ELP (Echinagard-Madaus AG) moderately sup-
pressed CYP3A4 expression in primary human hepatocytes.
In addition, Gorski et al. [11] found that Echinacea could
cause induction of CYP3A4 in intestinal cells, but suppressed
hepatic CYP3A4 expression. Both authors directly assayed
CYP activity alone, not the protein or mRNA steady-state
levels and their results may be influenced by the presence of
various Echinacea constituents that can inhibit CYP activity.
Thus, the ability of Echinacea to induce CYP expression is
still not well described and a more detailed characterization
is needed.
We have carried out such an analysis of CYP3A4
induction in human hepatocellular carcinoma HepG2 cells
by an ELP (Echinaforce), using real-time reverse tran-
scription polymerase chain reaction (RT-PCR) to deter-
mine steady-state mRNA levels. In addition, since alky-
lamides are important both for the therapeutic activity
of Echinacea [12] and its CYP inhibitory potency [13],
we investigated whether the isolated alkylamides: dodeca-
2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide (i), dodeca-
2E,4E-dienoic acid isobutylamide (ii), undeca-2E/Z-ene-
8,10-diyonic acid isobutylamides (iii) and dodec-2-ene-
8,10-diyonic acid isobutylamide (iv) (Figure 2) can induce
CYP3A4 transcription in the same system.
2. Methods
2.1. Chemicals. Hanks’ balanced salt solution (HBSS), foetal
bovine serum (FBS), minimal essential medium alpha with
Glutamax-1 (MEM-α) and hexamer random primers were
all obtained from Invitrogen (Paisley, UK) Rifampicin
HPLC grade, trypsin-EDTA, ethanol, thiazoyl blue tetra-
zolium bromide (MTT) cell culture tested, RNAse-DNAse
free water, dimethylformamide, hydrochloric acid, glacial
acetic acid and sodium dodecyl sulphate were purchased
from Sigma-Aldrich Ltd (Poole, Dorset, UK). Moloney
murine leukemia virus (M-MLV) reverse transcriptase and
reverse transcriptase buffer, deoxynucleotide triphosphates
(dNTP) and recombinant RNAsin ribonuclease inhibitor
were obtained from Promega (Southampton, UK) iQ SYBR
Green Supermix was purchased from BioRad Laboratories
Inc. (Hertfordshire, UK) and Nucleopsin RNA II kit from
Macherey-Nagel (Abgene, Epson, UK). Primers for β-actin,
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and
CYP3A4 were purchased as high quality, purified OliGold
Primers from Eurogentec Ltd. (Hampshire, UK) (Table 1).
The alkylamides dodeca-2E,4E,8Z,10E/Z-tetraenoic acid
isobutylamide (1), dodeca-2E,4E-dienoic acid isobutylamide
(2), undeca-2E/Z-ene-8,10-diyonic acid isobutylamides (3)
and dodec-2-ene-8,10-diyonic acid isobutylamide (4) were
purchased from Phytolab GmbH and Co. KG, (Vestenbergs-
greuth, Germany). Echinaforce (batch no: 018451) was a
kind gift from Bioforce, Switzerland.
2.2. Cell Culture. HepG2 cells were a generous gift from Pro-
fessor Ruth Duncan (Cardiff University, UK). HepG2 cells
were routinely cultured in MEM-α supplemented with
Glutamax and 10% FBS, subcultured at ∼70% confluence
and discarded after 10 passages. The cells were kept in a
humidified 37◦C incubator with 5% CO2.
2.3. Cell Viability Assay. The thiazoyl blue tetrazolium bro-
mide (MTT) assay was used to determine cell viability. The
assay was performed based on the protocol described by
Hansen et al. [14]. HepG2 cells were seeded at a density of
5000 cells per well in flat bottomed 96-well microtitre plates
(NUNC, Fisher Scientific, Leicestershire, UK) in 100 μl of
medium and allowed to attach for 48 h. The medium was
then removed and replaced with fresh medium containing
the test substance. The ethanol carried over from the extract
or the alkylamide stock solutions was kept below 0.1% to
prevent enzyme denaturation and cytotoxicity. 1 : 3 serial
dilution series was made from working stock solutions of
the Echinacea extract (Echinaforce) and the alkyalmides. For
Echinaforce two different working solutions were prepared:
11.6 and 64 μg mL−1. The 11.6 μg mL−1 working solution was
prepared by simply diluting neat Echinaforce with media.
To prepare the 64 μg mL−1 working solution, while keeping
the ethanol content below 0.1%, Echinaforce was dried in
a rotary evaporator, freeze dried, re-dissolved in ethanol to
yield a concentration of 85.85 mg mL−1 and then diluted to
64 μg mL−1 with media. Alkylamide working solutions were
prepared by diluting ethanolic stock solutions to 3 μM with
media, keeping ethanol concentration at 0.1%. A solvent
control containing just medium with 0.1% ethanol was
also included. Fresh test substance-containing medium was
added daily for 4 days. Then the medium was removed,
prior to adding 100 μl assay media and 20 μl MTT solution
(5 mg mL−1 in phosphate buffered saline). The plate was
incubated at 37◦C for 4 h before adding 150 μl of solubiliza-
tion solution (20% SDS 40% DMF, 2% glacial acetic acid
and 1% vol/vol HCl in distilled water, pH 4.7) and leaving
the plate to develop overnight. Formazan production was
quantified by determining the absorbance at a wavelength
of 560 nm using a plate reader (Labsystems Multiscan, VWR
International).
2.4. Cell Treatment for Induction Studies. 300 000 cells
were seeded in 25 cm2 tissue culture flasks and left to
adhere for 24 h. The medium was then replaced with fresh
medium containing the test-substance (Echinaforce: 22, 11.6,
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Figure 1: The control of CYP protein levels by HMP. Components of the HMP can either bind the AhR and CAR causing their translocation
to the nucleus, or bind the inactive PXR in the nucleus and activate it. Following this binding step, AhR/CAR and PXR can initiate a
sequence of events that increases CYP mRNA production and consequently increased CYP protein production. Increased CYP protein levels
can accelerate drug metabolism, pro-drug activation and bioactivation. CYP3A4 transcription is mainly controlled by PXR. Increase in
mRNA levels can be detected by quantification with real time RT-PCR. Another possibility is that HMP components may also affect post
translational modifications such as ubiquitination, which results in protein degradation. This can lead to a change in CYP protein levels
without affecting mRNA levels.
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Figure 2: Structures of alkylamides assessed for CYP3A4 mRNA expression: (a) dodeca-2E, 4E,8Z, 10E/Z-tetraenoic acid isobutylamides
(1), (b) dodeca-2E,4E-dienoic acid isobutylamide (2), (c) undeca-2E/Z-ene-8,10-diyonic acid isobutylamides (3) and (d) dodec-2-ene-8,10-
diyonic acid isobutylamide (4).
1.16 μg mL−1, alkylamides: 1.62, 44 nM). Rifampicin at a
concentration of 50 μM was used as a positive control
for CYP3A4 activation and the solvent control contained
medium with 0.1% ethanol. The test substance containing
medium was prepared by diluting neat Echinaforce, a stock
solution of alkylamide, or a stock solution of rifampicin
directly into the media ensuring that the concentration of
ethanol did not exceed 0.1%. Fresh test substance-containing
medium was added daily for 4 days, before RNA isolation for
real-time RT-PCR.
2.5. RNA Isolation. Cells were harvested using trypsin–
EDTA and total RNA was extracted using the Nucleospin
RNA II kit, according to the manufacturer’s instructions.
The RNA was quantified spectrophotometrically by measur-
ing absorbance (Abs) at 260 nm (NanoDrop ND 1000 UV
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Table 1: β-actin, GAPDH and CYP3A4 primers.
Gene Gene accession no. Primer Sequence Concentration (nM) Product size
β-Actin X00351
Forward 5′-TCAGCAAGCAGGAGTATG-3′ 300
97
Reverse 5′-GTCAAGAAAGGGTGTAACG-3′ 300
GAPDH NM 002046
Forward 5′-TCTCTGCTCCTCCTGTTC-3′ 900
120
Reverse 5′-GCCCAATACGACCAAATCC-3′ 900
CYP3A4 NM 017460
Forward 5′-ATCATTGCTGTCTCCAACCTTCAC-3′ 200
103
Reverse 5′-TGCTTCCCGCCTCAGATTTCTC-3′ 200
Genebank accession numbers, primer sequences, concentrations and product sizes are shown all genes.
Spectrophotometer). The purity of the final preparations was
determined by calculating the ratios Abs 260/280.
2.6. Reverse Transcription. For each sample, 2.5 μg of total
RNA was reverse transcribed using M-MLV Reverse Tran-
scriptase according to the manufacturer’s instructions.
Briefly, RNA was diluted to 125 ng mL−1, then 7 μl of 5×
reaction buffer, 4 μl dNTP (10 mM each), 1 μl RNase in-
hibitor and 1 μl hexamer primers were added to 20 μl of
diluted RNA on ice. The mixture was heated at 65◦C for
10 min and then snap-cooled on ice for 2 min, prior to the
addition of 2 μl of reverse transcriptase (200 units μl−1). The
reaction was carried out at 42◦C for 90 min. The cDNA was
stored at −80◦C until further use.
2.7. Real-Time PCR. The sequences of the primers used
for real-time PCR are shown in Table 1 along with the
Genebank accession numbers of the cDNA sequences used
for primer design. Primer selection was accomplished by
using the Beacon designer 5.1 software suite (Premier Biosoft
International, Palo Alto USA). The primer concentration was
optimized to achieve 98–100% amplification efficiency (data
not shown).
Real-time PCR analysis was carried out using an iCycler
iQ optical system multicolour real-time PCR detection sys-
tem with the iCycler optical system software version 3.1 (Bio-
rad Laboratories Inc). The samples were prepared by mixing
10 μM of each primer, 25 μl 2× iQ SYBR Green Supermix,
2 μl of 1 : 10 diluted cDNA and the appropriate volume of
nuclease-free water. Two 20 μl aliquots were used for the
amplification reaction. All reactions were run in duplicate.
The hot start polymerase was activated by heating at 95◦C
for 3 min. The cycling conditions were: 0.1 min at 95◦C
(melting) and 0.45 min at 55◦C (annealing and extension).
Threshold values (Ct) were calculated automatically by the
software.
The Ct data was processed according to the method
described by Pfaffl [15]. Briefly, the Pfaffl equation [15] was
first used to calculate the relative gene expression ratio, that
is, the change in target gene expression divided by the change
in the reference gene expression.
R = E
ΔCttarget (Meancontrol−Meantreatment)
target
E
ΔCtreference (Meancontrol−Meantreatment)
reference
, (1)
where R is the relative gene expression ratio, E is the
amplification efficiency (E = 2 at 100% efficiency) and ΔCt
is the difference in threshold (Ct) value.
Then the R values were normalized with respect to the
vehicle control. Statistical significance was determined using
the relative expression software tool (REST), a randomiza-
tion test developed by Pfaffl et al. [16].
3. Results
3.1. Determination of Clinically Relevant Concentration
Ranges. Based on the results and predictions by other groups
[10, 12, 17], we determined that the clinically relevant Echi-
naforce concentration range lies between 1 and 25 μg mL−1.
For the alkylamides the clinically relevant concentrations
were taken from Woelkart et al. [18, 19], who found that
alkylamide (1) reached the highest plasma concentration
of 44 or 1.62 nM in human volunteers dosed with an E.
angustifolia root extract and Echinaforce, respectively [18,
19].
3.2. Cell Viability Assay. The viability of HepG2 cells exposed
to Echinaforce (up to 64 μg mL−1), ethanol (up to 0.1%)
or each of the alkylamides (up to 3 μM), for 96 h was
investigated in the MTT assay. No loss of cell viability was
observed.
3.3. Real-Time PCR Analysis. To determine if Echinaforce
and its alkylamides can change the steady-state mRNA levels
of CYP3A4, we exposed HepG2 cells to Echinaforce or
alkylamides over a period of 96 h. Rifampicin was used as
the positive control and plain medium with 0.1% ethanol
was used as the vehicle control. Following treatment, the
mRNA was extracted and the levels of CYP3A4 mRNA
were quantified by real time RT-PCR using β-actin as
the internal control (reference gene). It has been reported
that Echinaforce can up-regulate β-actin in human mono-
cytes/macrophages [12]. Therefore, a second reference gene,
GAPDH, was used to detect β-actin up-regulation. We found
that exposure to Echinaforce (Figure 3) or the alkylamides
(data not shown) did not result in up-regulation of β-
actin expression in HepG2 cells, allowing β-actin to be used
reliably as an internal control. Melt-curve analysis confirmed
the absence of non-specific amplification products (data
now shown). The results of the real time PCR analysis
are shown in Figure 4 and Table 2. Exposure to rifampicin
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Figure 3: Relative CYP3A4 mRNA expression (fold increase over
vehicle control) for β-actin using GAPDH as the reference gene, fol-
lowing treatment of HepG2 cells with Echinaforce (E: 22 μg mL−1)
or with vehicle control [0.1% ethanol (EtOH)] for 96 h. A value of
1 denotes no increase over the control. The values are the average of
three independent experiments ± SE.
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Figure 4: Relative CYP3A4 mRNA expression (fold increase over
vehicle control) for CYP3A4 in HepG2 cells after a 96 h treatments
with: 50 μM rifampicin (R), Echinaforce (E1: 1.16 μg mL−1, E2:
11.6 μg mL−1, E3: 22 μg mL−1), alkylamide 1 (1A: 1.62 nM, 1B:
40 nM), alkylamide 2 (2A: 1.62 nM, 2B: 40 nM), alkylamide 3 (3A:
1.62 nM, 3B: 44 nM) and alkylamide 4 (4A: 1.62 nM, 4B: 44 nM).
A value of 1 denotes no increase over the control. Values are
the average of three independent experiments ± SE. Statistically
significant results (P < .05 with a randomization assay) are marked
with ∗∗.
resulted in a statistically significant (P < .05) up-regulation
of CYP3A4 expression (3.8-fold) compared to the vehicle
control (0.1% ethanol) as shown in Table 2. In contrast,
exposure to Echinaforce or the alkylamides did not produce
any statistically significant changes (at the 5% level) in the
CYP3A4 mRNA levels (see Table 2).
Table 2: Induction of CYP3A4 gene expression in HepG2 cells by
Echinaforce and its alkylamides.
Treatment Concentration Relative CYP3A4
mRNA expressiona
(±) SE
Rifampicin 50 μM 3.83 1.39
Echinaforce
1.16 μg mL−1 1.16 1.03
11.6 μg mL−1 1.09 0.44
22 μg mL−1 1.08 0.28
Alkylamide 1
1.62 nM 1.03 0.69
44 nM 1.07 0.19
Alkylamide 2
1.62 nM 1.11 0.44
44 nM 0.95 0.52
Alkylamide 3
1.62 nM 0.98 0.46
44 nM 1.11 0.60
Alkylamide 4
1.62 nM 1.08 0.22
44 nM 0.87 0.34
The cells were treated for 96 h, changing the test substance containing
medium every 24 h. Values are the average of three independent experiments
± SE.
aFold increase over the vehicle control.
4. Discussion
This is the first study to investigate the influence of an
Echinacea preparation (Echinaforce) and four alkylamides
on the steady state CYP3A4 mRNA level in HepG2 cells.
No statistically significant changes in the mRNA steady-
state level of CYP3A4 were observed after treating the cells
with clinically relevant concentrations of Echinaforce or any
of the alkylamides. In contrast, treatment with rifampicin
resulted in a 3.8-fold up-regulation of CYP3A4. This value
is in agreement with other studies with rifampicin [7,
20]. Therefore, we conclude that the compounds found
in Echinaforce and the alkylamides tested have no effect
on CYP3A4 transcriptional activity in HepG2 cells. It is
possible that Echinaforce or the alkylamides might induce
CYP3A4 expression at higher concentrations than the ones
we tested. However, this would be at levels well above the
clinically relevant range and, thus, would have no practical
significance.
The effect of Echinaforce on the induction of other CYP
enzymes has not been investigated and the apparent inability
of Echinaforce to induce CYP3A4 does not imply that this
will be the case for the remaining isoforms. However, due
to the prominent role of CYP3A4 in drug metabolism any
alteration of CYP3A4 activity is a major contributor to HMP-
drug interactions.
It is important to note that we investigated mRNA
steady-state levels instead of the actual CYP3A4 protein
expression. Therefore, it is not possible to rule out that
Echinaforce might affect the post-translational regulation
of CYP3A4 expression (Figure 1). Several types of post-
translational regulation for CYPs have been documented
including ubiquitination, nitration and phosphorylation
[21]; however, we are not aware of published work suggesting
that CYP post-translational regulation can be affected by
HMPs.
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Hellum et al. [10] found that two other Echinacea prepa-
rations (Echinagard and Madaus AG) caused a small, but
significant suppression of CYP3A4 activity in cultured
primary human hepatocytes. This discrepancy could be the
result of the differences in methodology. Hellum et al.
[10] exposed the cells to much higher (4–80 times, i.g.,
4.735–473.5 μg mL−1) Echinacea purpurea concentrations,
and assayed enzyme activity instead of determining mRNA
levels. We have previously shown [6] that Echinacea prepara-
tions can directly inhibit CYP3A4. Hence, it is possible that
the reduction in CYP3A4 activity observed [10] is not in fact
related to reduced CYP3A4 expression, but rather a direct
inhibitory effect on its enzyme activity. A time course study
would have to be carried out to distinguish between reduced
expression and direct enzyme inhibition.
Although without effect on CYP3A4 mRNA levels, the
Echinacea extract (Echinaforce) concentrations tested here
were sufficient to cause observable inhibition of CYP3A4
activity. The IC50 for CYP3A4 inhibition estimated for
Echinacea [6] was 27.2 μg mL−1, close to the 22 μg mL−1
employed in the present CYP induction study.
HepG2 cells are a human hepatocarcinoma cell line and
thus, they do not exactly mirror the CYP profile present
in the human liver. However, the mechanism controlling
CYP3A4 expression in HepG2 cells are identical to those of
human hepatocytes and thus, if Echinaforce does not induce
CYP3A4 in HepG2 cells it is highly likely that it will not do so
in human hepatocytes either. Therefore, overall, our results
suggest that CYP3A4 induction can presumably be excluded
as an avenue for interactions between Echinaforce or its
alkylamides (the major active constituents) and conventional
medicines thus reducing the risk of adverse effects arising
from such interactions. Overall, this data improves our
understanding of the safety profile of Echinacea. It also shows
that Echinacea extracts are unlikely to cause cytochrome
P450 mediated interactions with conventional medicines
[22]. This is in agreement with the phamacovigilance data, as
there is a lack of reports documenting interactions between
Echinacea and concurrently used medication.
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